Search Results 601-610 of 15135 for alt

1. A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment - Mayo Clinic

   ALT < 400 IU/L;; AST/ALT > 1.5. Maddrey's discriminant function ≥ 32 assuming a control prothrombin time of 12 seconds. Model for End-stage Liver Disease ...

2. A Study to Assess Dendritic Cell Immunotherapy Plus Standard-of-Care to Treat Advanced Renal Cell Carcinoma - Mayo Clinic

   Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5 x ULN or, AST and ALT 5 x ULN if liver function abnormalities are due to underlying

3. FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study - Mayo Clinic

   AST or ALT >400 U/L. 7. mDF <32 or >70 at Screening 8. MELD score <18 or >25 at Screening. 9. Other causes of liver disease including chronic hepatitis B ...

4. A Study to Investigate the Effectiveness and Safety of Cannabidiol as an Additional Treatment for Seizures Associated with Lennox-Gastaut Syndrome in Children and Adults - Mayo Clinic

   Alanine aminotransferase [ALT] >5 x upper limit of normal [ULN] or total bilirubin [TBL] >2 x ULN; OR the ALT or Aspartate aminotransferase (AST) >3 x ULN ...

5. CardiolRx In Recurrent Pericarditis Following IL-1 Blocker Cessation - Mayo Clinic

   Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 times the upper limit of normal (ULN) or ALT or AST \> 3x ULN plus ...

6. CATALINA-2: A Clinical Study Of TORL-1-23 In Platinum-resistant Ovarian Cancer.

   ... ALT (SGPT): ≤3 X ULN (participants with active liver metastases who have ALT/AST ≤5 X ULN may be enrolled) * Albumin: ≥2.5 g/dL * ECG: 12-Lead ECG with ...

7. Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia - Mayo Clinic

   Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN; Calculated creatinine clearance (CrCl) of ≥ 45 mL/min; Life expectancy > 24 weeks ...

8. A Study to Evaluate the Safety and Effectiveness of BMS-986036 (pegbelfermin) in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Fibrosis - Mayo Clinic

   Evidence of significant worsening of ALT, AST or bilirubin during the Screening Period, in the opinion of the investigator or medical monitor. A centrally read ...

9. Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma - Mayo Clinic

   ... ALT\]) ≤ 10 x ULN\* * Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L * Shortening fraction of ≥ 27% by ...

10. A Study to Collect Information about Biomarkers (Lab Test Results) that May Help to Predict Which People with Calf Vein Clots May be at Higher or Lower Risk of Having the Clot Grow or Progress - Mayo Clinic

    Significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or ALT > 3 x ULN. (within last two weeks); Platelet count < 50 x109/L ...